Diminishing Though Impressive Returns in Genomics
This article was originally published in Start Up
Executive Summary
While average returns to investors in the genomics IPOs completed so far this year are slightly off from those in previous years, they're still outpacing those of their non-genomics, biopharmaceutical counterparts.